Sutro Biopharma Inc (STRO) Financial Statements

STRO Financial Data

EBITDA—

Revenue (TTM)—

Gross Profit (TTM)—

Gross Margin—

Operating Margin—

ROE—

ROA—

Debt/Equity—

Current Ratio—

FCF—

FCF Yield—

Piotroski F-Score—

Rev/Share (TTM)—

50-Day MA—

200-Day MA—

Shares Outstanding—

STRO Computed Insights

FCF$-178.93M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

STRO Financial Statements & Data

Sutro Biopharma Inc (STRO) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Sutro Biopharma Inc's financial performance and position as a Healthcare company.

Free cash flow (FCF) is $-178.93M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Sutro Biopharma Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.